Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing

Cancer Research

Volumn 65, Issue 22, 2005, Pages 10569-10577

  Wang, Li Xin ^a,b   Li, Rui ^a   Yang, Guojun ^a   Lim, May ^a   O'Hara, Aisling ^a   Chu, Yiwei ^a,c   Fox, Bernard A ^a   Restifo, Nicholas P ^d   Urba, Walter J ^a   Hu, Hong Ming ^a,e  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d NATIONAL CANCER INSTITUTE   (United States)

^e EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; GLYCOPROTEIN GP 100; INTERLEUKIN 15; INTERLEUKIN 7; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFER; CONTROLLED STUDY; DENDRITIC CELL; HOMEOSTASIS; IRRADIATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MELANOMA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENICS; TUMOR IMMUNOLOGY; TUMOR REGRESSION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-15; INTERLEUKIN-7; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS;

EID: 28544446699     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2117     Document Type: Article

References (40)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
2. Surh CD, Sprent J. Homeostatic T cell proliferation: how far can T cells be activated to self-ligands? J Exp Med 2000;192:F9-14.
3. Mackall CL, Bare CV, Granger LA, Sharrow SO, Titus JA, Gress RE. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol 1996;156:4609-16.
4. Borrello I, Sotomayor EM, Rattis FM, Cooke SK, Gu L, Levitsky HI. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 2000;95:3011-9.
5. Asavaroengchai W, Kotera Y, Mule JJ. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci U S A 2002;99:931-6.
6. Dummer W, Niethammer AG, Baccala R, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 2002;110:185-92.
7. Hu HM, Poehlein CH, Urba WJ, Fox BA. Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 2002;62:3914-9.
8. Ma J, Urba WJ, Si L, Wang Y, Fox BA, Hu HM. Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol 2003;33:2123-32.
9. Wu Z, Bensinger SJ, Zhang J, et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004;10:87-92.
10. King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004;117:265-77.
11. Rosenberg SA, Yang JC, Restifo NP. Reply to "Cancer vaccines: pessimism in check." Nat Med 2004;10:1279-80.
12. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
13. Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 2004;101 Suppl 2:14639-45.
14. Robbins PF, Dudley ME, Wunderlich J, et al. Cutting edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004;173:7125-30.
15. + T cells. J Exp Med 2003;198:569-80.
16. Maine GN, Mule JJ. Making room for T cells. J Clin Invest 2002;110:157-9.
17. Ge Q, Hu H, Eisen HN, Chen J. Different contributions of thymopoiesis and homeostasis-driven proliferation to the reconstitution of naive and memory T cell compartments. Proc Natl Acad Sci U S A 2002;99:2989-94.
18. Opferman JT, Ober BT, Ashton-Rickardt PG. Linear differentiation of cytotoxic effectors into memory T lymphocytes. Science 1999;283:1745-8.
19. Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003;4:225-34.
20. Madakamutil LT, Christen U, Lena CJ, et al. CD8αα-mediated survival and differentiation of CD8 memory T cell precursors. Science 2004;304:590-3.
21. + memory T cell subsets. Proc Natl Acad Sci U S A 2004; 101:5610-5.
22. Judge AD, Zhang X, Fujii H, Surh CD, Sprent J. Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8(+) T cells. J Exp Med 2002;196:935-46.
23. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003;3:269-79.
24. + T cells. J Exp Med 2002;195:1533-9.
25. Lodolce JP, Boone DL, Chai S, et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998;9:669-76.
26. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
27. Jameson SC. Maintaining the norm: T-cell homeostasis. Nat Rev Immunol 2002;2:547-56.
28. + cells. J Exp Med 2002;195:1523-32.
29. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003;4:1191-8.
30. Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004;4:841-55.
31. + T cells. Proc Natl Acad Sci U S A 2002;99:8832-7.
32. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005; 174:2591-601.
33. Stockinger B, Kassiotis G, Bourgeois C. Homeostasis and T cell regulation. Curr Opin Immunol 2004;16:775-9.
34. Lou Y, Wang G, Lizee G, et al. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res 2004;64:6783-90.
35. + T cells. Proc Natl Acad Sci U S A 2004;101:1969-74.
36. + T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol 2004; 173:900-9.
37. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48.
38. Bai XF, Liu J, Li O, Zheng P, Liu Y. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes. J Clin Invest 2003;111:1487-96.
39. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4:762-74.
40. Rodriguez PC, Quiceno DG, Zabaleta J, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004;64:5839-49.